AMRI is to take additional actions to streamline its operations in 2012. During Q4 2011 AMRI has reduced its workforce, reduced capacity and reduced operating costs. The company hopes these actions "will better align the business to current and expected market conditions and are expected to improve the company’s overall cost competitiveness and increase cash flow generation". AMRI said the reduction will primarily affect its US operations and will terminate the lease of one of its US facilities. AMRI expects that these cost-reduction initiatives will result save $10-11m per year.
Times Union
Wednesday 28 December 2011
AMRI restructures for 2012
Tuesday 20 December 2011
Sunday 18 December 2011
GE and M+W to build biopharma manufacturing plants
GE Healthcare and M+W Group have formed a partnership to offer an integrated, "turn-key" approach for the construction of biopharmaceutical manufacturing plants, to help meet the rapidly increasing worldwide demand for these potentially life-saving treatments. The alliance is targeted at emerging countries.
Bloomberg BusinessWeek
Lonza expands early phase manufacturing in China
Lonza has completed the expansion of it snarly phase manufacturing capacity in Nansha, China. Lonza has added a new cGMP kilo-lab and an additional small scale train to meet the growing demands of its global small molecule customers.
Manufacturing Chemist
Tuesday 13 December 2011
EMA and FDA to collaborate on GMP inspections
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) are to share work on inspections of manufacturing sites in each other's territories, starting in January 2012. The initiative builds on a pilot programme which ran earlier this year. Initially the programme will focus on inspections of manufacturing sites in the EU or US that are already known to the two authorities and have a history of compliance with GMP following previous inspections.
InPharm
Australian biologics facility moves closer
DSM Biologics and the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology (AIBN) have signed a memorandum of understanding to construct and run Australia’s largest biologics scale-up facility in Brisbane. The Aus$65m facility, which is currently under construction, will be owned by Biopharmaceuticals Australia and will be run by DSM Biologics. The AIBN will collaborate on early stage biologics development.
Australian Life Scientist
Wednesday 7 December 2011
Novasep restructures balance sheet
Novasep has completed a restructuring of its balance sheet with its creditors. Additionally the French Fonds Stratégigue d’Investissement (French Strategic Investment Fund) has become a new investor in the company, which as abandoned its plans to merge with Minakem.
Speciality Chemicals
Tuesday 6 December 2011
Shasun aims for growth
Shasun Pharmaceuticals Managing Director S Abhaya Kumar has said the company aims to double its annual revenues to $389m, within four years, by increasing exports. The company is currently adding new API manufacturing capacity in Vizag, India, and expanding capacity in Newcastle, UK.
Economic Times
Monday 5 December 2011
Thursday 1 December 2011
Vivimed acquires Uquifa
Vivimed Labs has acquired Yule Catto's Uquifa pharmaceutical ingredients business for £35m. Uquifa operates three manufacturing sites, two in Spain and one in Mexico. Mark Robbins will remain CEO of Uquifa. Vivimed said the acquisition would strengthen its current position in pharma APIs and intermediates while significantly improving the cost competitiveness of Uquifa.
Economic Times
Subscribe to:
Posts (Atom)
